Versantis is developing breakthrough orphan drugs in liver and pediatric diseases addressing high unmet medical needs.

Based on its proprietary detoxification platform technology Versantis is pursuing innovative therapies for the critical care of serious liver conditions such as acute on chronic liver failure or urea cycle disorder (UCD). Its lead candidate, VS-01, is currently being evaluated at clinical stage and has the potential to be the first treatment for acute on chronic liver disease, simultaneously supporting multiple failing organs.